Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Post by biorunon Apr 24, 2023 2:12pm
260 Views
Post# 35410815

biotech is slow and cool

biotech is slow and coolUntil it's not.

This is what I would like to see:

Anti aging results that draw competitive interest from the big cats

Evidence of product launch with AbbVie 1067

Royalty rate disclosure with a sales forecast or some numbers showing up on the books.

Announcement of a pets deal

Announcement of a human diabetes deal

Announcement that the CEO will step aside and let a fully seasoned Biotech exec from a mid or large cap step in and sell the company, for what the science is really worth. NPV of all the aforementioned deals 

All of this is possible theoretically speaking, with the science factually represented and as it stands.

We don't need to bone on about what the problem is, because we all heard it every day for last 2 years and there is nothing we can do about it.

 
<< Previous
Bullboard Posts
Next >>